The REVAMP trial: key questions remain

Lancet. 2024 Jan 6;403(10421):28-29. doi: 10.1016/S0140-6736(23)01919-0.

Authors

Tomohiko Sato¹, Ryu Yanagisawa²

Affiliations

¹ Division of Transfusion Medicine and Cell Therapy, The Jikei University Hospital, Tokyo 1058471, Japan. Electronic address: tomosatou@jikei.ac.jp.
² Division of Blood Transfusion, Shinshu University Hospital, Nagano, Japan.

PMID: 38184334
DOI: 10.1016/S0140-6736(23)01919-0

No abstract available

Publication types

Letter